L. Wunderle

发表

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

K. Bhalla, H. Kantarjian, J. Cortes, 2006, The New England journal of medicine.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

J. Oldenburg, A. Pavlova, A. Hochhaus, 2007, Blood.

Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy.

G. Baumann, K. Wernecke, S. Felix, 2004, Journal of the American College of Cardiology.

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

U. Dührsen, H. Serve, O. Ottmann, 2012, Leukemia.

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib

P. Erben, R. Hehlmann, A. Hochhaus, 2008, Haematologica.

Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede

J. Oldenburg, A. Pavlova, A. Hochhaus, 2007 .

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.

D. Nowak, W. Hofmann, A. Hüttmann, 2018, Blood.

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

S. Schnittger, H. Serve, Sebastian A. Wagner, 2020, BMC pharmacology & toxicology.

Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia

S. Stilgenbauer, L. Bergmann, B. Schlegelberger, 2011, European journal of haematology.

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

K. Bhalla, H. Kantarjian, J. Cortes, 2005 .

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options

S. Schnittger, O. Ottmann, L. Wunderle, 2017, The American journal of case reports.

Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL)

U. Dührsen, O. Ottmann, L. Wunderle, 2007, Cancer.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

J. Oldenburg, H. Gschaidmeier, A. Pavlova, 2005 .

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

H. Gschaidmeier, A. Hochhaus, O. Ottmann, 2005 .

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

H. Serve, A. Wolf, L. Wunderle, 2013 .

otential Role of Humoral Immunity n Cardiac Dysfunction of Patients uffering From Dilated Cardiomyopathy

G. Baumann, S. Felix, M. Dörr, 2016 .